Patient Endorsement of the Outcome Measures in Rheumatology OMERACT Total Joint Replacement TJR clinical trial draft core domain setReportar como inadecuado

Patient Endorsement of the Outcome Measures in Rheumatology OMERACT Total Joint Replacement TJR clinical trial draft core domain set - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

BMC Musculoskeletal Disorders

, 18:111

Clinical rheumatology and osteoporosis


BackgroundA patient- and surgeon-Delphi-derived Outcome Measures in Rheumatology OMERACT draft core domain set for total joint arthroplasty TJR trials was recently developed. Our objective was to obtain further patient stakeholder endorsement of draft core domain set for TJR clinical trials.

MethodsWe surveyed two patient groups: 1 OMERACT patient partners; and 2 patients who had undergone hip or knee TJR. Patients received an introductory email with explanations about the core domain set and instructions to rate the core domains, i.e., important aspects, of OMERACT TJR clinical trial draft core domain set. Rating was on a nominal scale, where 1–3 indicated a domain of limited importance, 4–6 an important, but not critical domain, and 7–9 a critical domain. We used Mann–Whitney test a non-parametric test to compare the distribution of ratings between the two groups.

ResultsThirty one survey participants from the OMERACT patient partner group and 118 knee-hip TJR patients responded with response rates of 66 and 80%, respectively. Majority of the survey respondents were female, 87 vs. 53%, and were 55 years or older, 57 vs. 94%. Median interquartile range IQR scores for six core domains by OMERACT and knee-hip TJR patient groups were, respectively: pain, 8 8, 9 and 9 8, 9; function, 9 8, 9 and 9 8, 9; patient satisfaction, 8 8, 9 and 8 7, 9; revision surgery, 7 7, 8 and 7 5, 9; adverse events, 8 7, 9 and 8 6, 9; and death, 9 6, 9 and 9 4, 9. No statistically significant differences in rating were noted for any of the six core domains between the two groups p ≥ 0.31. Among the additional domains, ratings for patient participation did not differ by group p = 0.98, but ratings for cost were significantly different p = 0.005. Patients provided qualitative feedback regarding core domains, and did not propose any modifications to the draft core domain set.

ConclusionsTwo separate patient stakeholder groups endorsed the OMERACT TJR draft core domain set for TJR trials.

AbbreviationsOMERACTOutcome Measures in Rheumatology

PRPsPatient research partner

SMARTSt. Vincent’s Melbourne Arthroplasty Registry

SVPHSt. Vincent’s Private Hospital

TJRTotal Joint Replacement

WGWorking Group

Electronic supplementary materialThe online version of this article doi:10.1186-s12891-017-1464-x contains supplementary material, which is available to authorized users.

Download fulltext PDF

Autor: Jasvinder A. Singh - Michelle Dowsey - Peter F. Choong


Documentos relacionados